Under the release of good performance, the performance of the "minimally invasive department" was mixed.
As of March 6, MicroPort (00853HK) fell 056%, Minimally Invasive Robot-B (02252.)HK) fell 140%, Minimally Invasive Brain Science (02172.)HK) fell 107%, Cardiac Medical (688016SH) fell 006%, Cardioflow Medical-B (02160) rose 413%。
On the news side, on March 5, MicroPort and its subsidiary MicroPort Robotics successively released 2023 performance forecasts, and during the reporting period, the net losses of the above two companies have narrowed slightly.
Specifically, it benefited from the launch of new products and the drive of commercial promotionMinimally invasive medicineSales revenue for the full year ended December 31, 2023 is expected to increase by more than 15% year-on-year; The expected loss during the period will not exceed 5$800 million, compared to a loss of $5 in the same period in 2022$8.8 billion.
In fact, MicroPort Medical plays the role of an incubator to a certain extent, and its subsidiaries are involved in multiple medical subfields, forming a diversified business layout.
In terms of business, Cardiac Healthcare (688016.) is engaged in aortic and peripheral vascular interventionSH) revenue increased by more than 32% year-on-year; Minimally Invasive Brain Science (02172.) incubated by the neurointerventional businessHK) revenue increased by approximately 22% year-on-year; Heart Valve Business Spawned Cardioflow Medical (02160.).HK) revenue increased by approximately 31% to 36% year-on-year; The minimally invasive robot (02252.) born from the surgical robot business (02252HK) revenue increased by more than 350% year-on-year.
On the same day,Minimally invasive roboticsIt also announced a performance forecast, and it is expected that the net loss in 2023 will not exceed 10500 million yuan (RMB, the same below), compared with 11The net loss of 4.6 billion yuan narrowed.
The expected loss decreased, which the company said was mainly due to the increase in gross profit due to the increase in operating income; and focus on core R&D projects, improving R&D efficiency and reducing R&D expenses.
Of course, in addition to minimally invasive robots, Cardioflow Medical-B, Minimally Invasive Brain Science, and Xinmai Medical, which are also "minimally invasive", have all achieved positive growth in performance.
As early as the end of February,Cardioflow-b announced that it expects revenue for the year ended December 31, 2023 to be 3300 million to 3$0.4 billion, compared to the revenue for the year ended December 31, 2022$5.1 billion, an increase of about 31% to 36%.
In terms of growth, Cardioflow said that the continued progress of transcatheter aortic valve implantation ("T**I") products in China has driven a rapid increase in implant volume and revenue. In addition, T**i's products also continued to expand in overseas markets, resulting in an increase in revenue.
During the Reporting Period, Cardioflow's T**I products were added to 117 hospitals in China, representing a year-on-year increase of approximately 27%; The number of implants increased by about 45% compared to 2022. As of December 31, 2023, its t**i products have entered nearly 100 hospitals in Argentina, Colombia, Thailand and Russia, and a total of 120 overseas commercial implants have been completed, an increase of about 90% over 2022.
In terms of business progress, Cardioflow also mentioned that the third-generation T**I product, Vitaflow III, has submitted an application for registration to the National Medical Products Administration ("NMPA"). Transcatheter mitral valve replacement products have completed 10 cases of humanitarian application and continue to promote clinical follow-up, and type testing has been initiated. The left atrial appendage occluder product Anchorman has obtained the registration approval issued by the State Food and Drug Administration, and the manufacturing license issued by the local drug regulatory department.
Previously,Minimally invasive brain scienceThe company issued a positive profit forecast, saying that the company achieved significant revenue growth thanks to the continuous market expansion of a number of market-leading products and the accelerated access of newly approved products.
In 2023, the company expects to record an adjusted net profit of no less than 17.8 billion yuan, a year-on-year increase of at least about 36%; Compared with the loss of 24.68 million yuan in the previous year, the net profit will turn into a profit in 2023 and grow strongly.
Coincidentally, it was spun off and listed on the Science and Technology Innovation BoardCardio MedicineIt is also expected that the net profit attributable to the parent company will maintain a growth momentum in 2023.
During the reporting period, Xinmai Medical expects to achieve operating income of 117.4 billion to 120.1 billion yuan, an increase of 31% to 34% year-on-year. It is expected that the net profit attributable to the parent company in 2023 will be 47.5 billion to 49.2 billion yuan, an increase of 33% to 38% year-on-year.
Overall, under the incubation of MicroPort, its subsidiaries have shined in their respective fields and achieved rapid growth and innovative development. Among them, some subsidiaries have not only achieved certain results in the domestic market, but also gained a good reputation and influence in the international market.
However, it is worth reminding that in recent years, MicroPort's strategy of spinning off and listing has not been able to reverse its loss, and last year, MicroPort also spun off its heart rhythm management business and planned to list on the Hong Kong Stock Exchange, which to a certain extent triggered market concerns about the hollowing out of MicroPort, and was also one of the root causes of its stock price falling endlessly.
According to Futubull data, it has hit 72. since the end of June 2021Since the high of HK$85, the share price of MicroPort has continued to decline, and the cumulative decline has exceeded 90% so far.
Author: Hong Xiaodou.